Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Fulcrum Therapeutics
Fulcrum Therapeutics
Sanofi pays $80M to add Roche-rivaling Fulcrum drug to phase 3 rare disease pipeline
Fierce Biotech
Mon, 05/13/24 - 11:25 am
Sanofi
Fulcrum Therapeutics
Roche
GSK
Rare Diseases
clinical trials
losmapimod
Fulcrum's sickle cell disease program is back in business after FDA lifts 6-month hold
Fierce Biotech
Tue, 08/22/23 - 10:01 am
Fulcrum Therapeutics
sickle cell disease
clinical trials
FDX-6058
FDA placed hold on Fulcrum's sickle cell therapy over hematological malignancy concerns
Fierce Biotech
Thu, 03/9/23 - 11:43 am
FDA
Fulcrum Therapeutics
sickle cell therapy
FDX-6058
clinical hold
With CEO search, PhIII study underway, Fulcrum Therapeutics raises $125M from stock offering
Endpoints
Wed, 01/18/23 - 10:44 am
Fulcrum Therapeutics
Pharma CEOs
Aiming to brush last year's flop aside, Fulcrum sees shares skyrocket on early look at sickle cell program
Endpoints
Wed, 08/11/21 - 11:48 am
Fulcrum Therapeutics
GSK
clinical trials
FTX-6058
Second-quarter catalysts for the smaller players
EP Vantage
Wed, 04/7/21 - 10:25 am
AC Immune
Anavex
Santhera
IMMUTEP
Syndax
Novan
Fulcrum Therapeutics
BeyondSpring
Corbus
Orphazyme
Aldeyra
Adaptimmune
Inflarx
Sutro
Gemini Therapeutics
Fulcrum under pressure on underwhelming losmapimod data in type of muscular dystrophy
Seeking Alpha
Tue, 08/11/20 - 11:39 am
Fulcrum Therapeutics
clinical trials
losmapimod
FSHD
Acceleron signs pulmonary research and discovery deal with Fulcrum Therapeutics
Pharmaceutical Business Review
Wed, 01/1/20 - 06:51 pm
Acceleron
Fulcrum Therapeutics
R&D
small molecule drugs
pulmonary
The Week Ahead In Biotech: Johnson & Johnson Kickstarts Big Pharma Earnings
Yahoo/Benzinga
Sun, 07/14/19 - 04:09 pm
Merck
relebactam
TapImmune
earnings
JNJ
Seattle Genetics
Abbott Labs
Intuitive Surgical
Mirum Pharmaceuticals
Fulcrum Therapeutics
Genmab
Genetic Disease Focused Fulcrum Therapeutics Files for $86 Million IPO
CP Wire
Mon, 06/24/19 - 09:32 am
Fulcrum Therapeutics
IPOs
FSHD
sickle cell disease
beta thalassemia
Genetic Disease Focused Fulcrum Therapeutics Files for $86 Million IPO
Mon, 06/24/19 - 09:29 am
Fulcrum Therapeutics
IPOs
FSHD
sickle cell disease
beta thalassemia
GSK punts a failed cardio drug to a biotech startup — which has a new development strategy in mind
Endpoints
Tue, 04/23/19 - 12:07 pm
GSK
losmapimod
Fulcrum Therapeutics
Working with Patients and a Fresh $80M, Fulcrum Eyes a 2019 IPO
Xconomy
Wed, 09/5/18 - 09:30 am
Fulcrum Therapeutics
IPOs
FSHD